You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK)創新藥APAD中國一期臨床研究完成首例入組給藥
阿思達克 08-17 17:47
遠大醫藥(00512.HK)公布,由集團自主研發、用於治療膿毒症的全球創新藥物APAD,在中國進行的一期臨床試驗於近日完成首例受試者入組給藥。 該研究是一項隨機、雙盲、劑量遞增、安慰劑對照的一期臨床研究,旨在評價APAD在健康受試者中單次和多次靜脈給藥的安全性、耐受性和藥代動力學特徵。 遠大醫藥表示,此將為集團在呼吸及重症抗感染板塊的又一重要進展,預期APAD可與集團另一款全球創新產品STC3141形成互補,在膿毒症等重症治療方面形成良好產品組合。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account